BioCryst advances two new plasma kallikrein inhibitors in quest for HAE prophylactic

|About: BioCryst Pharmaceuticals, Inc. (BCRX)|By:, SA News Editor

BioCryst (BCRX) continues to work towards finding novel treatment options for HAE, as the company advances two optimized plasma kallikrein inhibitors into preclinicals.

The two candidates improved selectivity and bioavailability compared to BCX-4161 with "no effect on prothrombin time at high concentrations." (PR)

BCRX +7.5% premarket